Flindr Therapeutics

Flindr Therapeutics combines world-class science and expertise in translational biology, cancer target identification, immuno-oncology, and small-molecule oncology drug development. The expert team has a proven track record of success in the identification and development of covalent small-molecule inhibitors, from discovery to market approval. The company employs the "ImmunoGram drug discovery engine," which evolved from pioneering work conducted at the Netherlands Cancer Institute (NKI) and Oncode Institute laboratories. This approach reversely translates the heterogeneity of clinically common tumor-specific and host-specific factors into lab-based biological models, enabling the screening of the most critical drug targets associated with patient clinical responses.